HIV-1 fusion inhibitors (Beijing Institute of Pharmacology and Toxicology/Fudan University)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameHIV-1 fusion inhibitors (Beijing Institute of Pharmacology and Toxicology/Fudan University)
Drug Alias NameP26-BApc
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionTransmembrane glycoprotein gp41 inhibitors
TargetsTransmembrane glycoprotein gp41
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaPending
Originator CompaniesBeijing Institute for Drug Control
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBeijing Institute for Drug ControlFudan University
Active IndicationsN/A
Inactive IndicationsHIV Infections

Other Information

ATC CodeN/A
Related LinksN/A